Novo-backed CoLucid Pharmaceuticals secured $55m in the offering, and will use the proceeds to advance its migraine treatment through clinical trials.

The cancer therapeutics developer, backed by Novo and Immunocore, raised the cash less than a year after closing a nine-figure series A round.

Shareholder Johnson & Johnson bought stock in the molecular diagnostics technology provider as it floated in Brussels at a valuation of more than $500m.

Ligand acquired a 37% share in the biopharmaceutical company, which is set to float on Nasdaq, issuing three million shares priced at $8.00 each.

The app development platform, backed by Accenture, Juniper Networks, Sapphire Ventures and Norwest Venture Partners, had raised more than $200m in VC funding.

The Novartis and Johnson & Johnson-backed immuno-oncology company's shares opened at almost double their initial public offering value last week.

Cidara, which issued a 7.7% stake to Seachaid Pharmaceuticals last year, floated at the top of its range, raising $76.8m in the process.

The Hubert Burda-backed craft marketplace will float at the top of its range in an initial public offering that values it at roughly $1.8bn.

Existing shareholder Johnson & Johnson will buy $30m of stock in the cancer treatment developer as part of the offering.